Zevra Therapeutics (ZVRA) Accumulated Expenses (2014 - 2024)

Zevra Therapeutics (ZVRA) has 11 years of Accumulated Expenses data on file, last reported at $6.1 million in Q4 2024.

• Quarterly Accumulated Expenses fell 42.59% year-over-year to $6.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $6.1 million (down 42.59% YoY) and the FY2024 annual result came in at $6.1 million, down 42.59% from the prior year.
• Accumulated Expenses retreated to $6.1 million in Q4 2024, from $10.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.7 million in Q4 2023 to a low of $1.1 million in Q4 2021.
• A 5-year average of $4.1 million and a median of $1.7 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 537.84% — and 2024, when it plunged 42.59%.
• Tracing ZVRA's Accumulated Expenses over 5 years: stood at $1.2 million in 2020, then dropped by 8.98% to $1.1 million in 2021, then jumped by 58.73% to $1.7 million in 2022, then surged by 537.84% to $10.7 million in 2023, then sank by 42.59% to $6.1 million in 2024.
• The last three Accumulated Expenses figures came in at $6.1 million (Q4 2024), $10.7 million (Q4 2023), and $1.7 million (Q4 2022), per Business Quant data.